Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy (ARIES)

This study has been terminated.
(No results are avaialble as the study did not complete according to the protocol)
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: October 9, 2007
Last updated: February 6, 2013
Last verified: February 2013

The purpose of this survey is to describe long-term tolerance as seen under current conditions of use for anastrozole.

Breast Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Report Upon a Cohort of Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy for Hormone-dependant Breast Cancer. Long-term Tolerance Evaluation

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Enrollment: 1840
Study Start Date: November 2005
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Woman seen by their physician in the current care setting and for whom a treatment with anastrozole is decided by the physician (adjuvant treatment of breast cancer in postmenopausal women with hormone receptor positive status)


Inclusion Criteria:

  • woman treated with anastrozole as adjuvant therapy for hormone-dependant breast cancer in post-menopausal women with positive hormone-receptors
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00542594

Sponsors and Collaborators
Study Director: AstraZeneca France Medical Director AstraZeneca
  More Information

No publications provided

Responsible Party: AstraZeneca Identifier: NCT00542594     History of Changes
Other Study ID Numbers: NIS-OFR-ARI-2005/1
Study First Received: October 9, 2007
Last Updated: February 6, 2013
Health Authority: France: Conseil National de l'Ordre des Médecins
France: CCTIRS
France: CNIL

Keywords provided by AstraZeneca:
breast cancer

Additional relevant MeSH terms:
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Aromatase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on March 03, 2015